Key result
Screening using VCTE and CAP in patients with type 2 diabetes revealed severe steatosis in 60.3% and advanced fibrosis in 19.4%, with higher BMI significantly associated with both (P<0.05).
Why the study?
T2DM, obesity, hyperlipidemia, and hypertension are risk factors for NAFLD, prompting the assessment of steatosis and fibrosis severity in T2DM patients using VCTE and CAP.
What is the prevalence of severe steatosis and advanced fibrosis assessed by VCTE and CAP in patients with T2DM?
Cohort (n=776)
No
What is the prevalence of severe steatosis and advanced fibrosis assessed by VCTE and CAP in patients with T2DM?
p-value: p=<0.05
A high proportion of patients with T2DM have severe steatosis and advanced fibrosis, highlighting the need for individualized screening strategies based on BMI.
High prevalence in T2DM may inform screening considerations; leaves open whether BMI-guided VCTE/CAP improves outcomes.
Background: Type 2 diabetes mellitus (T2DM), obesity, hyperlipidemia, and hypertension are considered risk factors for developing non-alcoholic fatty liver disease (NAFLD). This study aims to assess steatosis and fibrosis severity in a cohort of T2DM patients, using vibration controlled transient elastography (VCTE) and controlled attenuation parameter (CAP). Material and method: We performed a prospective study in which, in each patient, we aimed for 10 valid CAP and liver stiffness measurements (LSM). To discriminate between fibrosis stages, we used the following VCTE cut-offs: F ≥ 2–8.2 kPa, F ≥ 3–9.7 kPa, and F4 - 13.6 kPa. To discriminate between steatosis stages, we used the following CAP cut-offs: S1 (mild) – 274 dB/m, S2 (moderate) – 290dB/m, S3 (severe) – 302dB/m. Results: During the study period, we screened 776 patients; 60.3% had severe steatosis, while 19.4% had advanced fibrosis. Female gender, BMI, waist circumference, elevated levels of AST, total cholesterol, triglycerides, blood glucose, and high LSM were associated with severe steatosis (all p-value < 0.05). BMI, waist circumference, elevated levels of AST, HbA1c, and CAP were associated with advanced fibrosis (all p-values < 0.05). Conclusion: Higher BMI (obesity) comprises a higher risk of developing severe steatosis and fibrosis. Individualized screening strategies should be established for NAFLD according to different BMI.
No takes yet. Share an insight, caveat, or question.
Sporea et al. (2020) conducted a cohort in Type 2 Diabetes Mellitus (n=776). Higher BMI and metabolic risk factors was evaluated on Severe steatosis and advanced fibrosis (p=<0.05). Screening using VCTE and CAP in patients with type 2 diabetes revealed severe steatosis in 60.3% and advanced fibrosis in 19.4%, with higher BMI significantly associated with both (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: